Table 1.
Characterization and validation.
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography | Normal | Fig. 1 Panel A |
| Phenotype | Immunocytochemistry | SOX2, OCT4, NANOG, SSEA-4 | Fig. 1 Panel A |
| Flow cytometry | TRA-1–60 (99.99%); NANOG (97.91%) SSEA-4 (99.60%) | Fig. 1 Panel B | |
| Genotype | Karyotype (G-banding) and resolution | 46XY Resolution: 475–525 |
Fig. 1 Panel C |
| Identity | Microsatellite PCR (mPCR) OR | Not performed | N/A |
| STR analysis | 16 sites tested, all sites matched | Available from the authors | |
| Mutation analysis (IF APPLICABLE) | Sequencing | Homozygous mutation of NPC1, c. 3182T> C (p. I1061T) | Fig. 1 Panel D |
| Southern Blot OR WGS | N/A | N/A | |
| Microbiology and virology | Mycoplasma | Mycoplasma testing by luminescence. Negative | Supplementary Fig. S1 |
| Differentiation potential | Teratoma formation | Teratoma with three germlayers formation. Ectoderm (neural epithelium); Mesoderm (cartilage); Endoderm (gut-like tissue) | Fig. 1 Panel F |
| Donor screening | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A | N/A |
| Genotype additional info | Blood group genotyping | N/A | N/A |
| HLA tissue typing | N/A | N/A |